All Trans Retinoic Acid
Hematopoietic And Lymphoid System Neoplasm
Explore 134 assets in Hematopoietic And Lymphoid System Neoplasm →Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital of Soochow University
Modality
UNKNOWN
Development Phase
Phase 2/3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05175508CT.gov Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hematopoietic And Lymphoid System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| All Trans Retinoic Acid (this asset) | The First Affiliated Hospital of Soochow University | P2/3 | CCC · 55 |
| Adriamycin | OHSU Knight Cancer Institute | P4 | BBB |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | BB |
| Dexasone | City of Hope Medical Center | P3 | BB |
| Fludarabine | National Cancer Institute (NCI) | P2 | BB |
| Allogeneic, Ex Vivo Expanded, Umbilical Cord Blood-Derived Hematopoietic Cd133+ Progenitor Cells- Cultured Fraction (Cf) | Gamida Cell ltd | P3 | BB |
| Teclistamab | Janssen Pharmaceutical K.K. | P2 | BB |
| Melphalan | Thomas Jefferson University | P2 | BB |
| Bortezomib | OHSU Knight Cancer Institute | P4 | BB |
+42 more in the Hematopoietic And Lymphoid System Neoplasm cohort
Other indications for All Trans Retinoic Acid
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myelodysplastic Syndrome | — | P2/3 | B · 57 |
| Acute Myeloid Leukemia | — | P2/3 | CCC · 55 |
| Prostate Neoplasm | — | P2 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- AdriamycinOHSU Knight Cancer InstituteBBB
- CyclophosphamideNational Cancer Institute (NCI)BB
- DexasoneCity of Hope Medical CenterBB
- FludarabineNational Cancer Institute (NCI)BB
- Allogeneic, Ex Vivo Expanded, Umbilical Cord Blood-Derived Hematopoietic Cd133+ Progenitor Cells- Cultured Fraction (Cf)Gamida Cell ltdBB
Citation
Floatz Terminal. All Trans Retinoic Acid in Hematopoietic And Lymphoid System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/all-trans-retinoic-acid-hematopoietic-and-lymphoid-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →